31.07.2023
Schellenberg Wittmer advised Santhera Pharmaceuticals Holding AG on the sale of its Raxone®/idebenone business for all indications worldwide to Chiesi Farmaceutici S.p.A. The transaction replaces the existing license …
20.07.2023
Schellenberg Wittmer acted as co-counsel for Sosei Heptares on its acquisition of Idorsia Pharmaceuticals Ltd's pharmaceuticals business in Japan and APAC.
Contact
Vibeke Berning Johansen
Head of Marketing & Communications
23.06.2023
Schellenberg Wittmer advised Swisscanto Private Equity in the CHF 8.3 million Series B financing of the leading innovator in ultrasonic camera technology Distran.
23.06.2023
Schellenberg Wittmer advised Sentinal Leasing AG on its latest ordinary capital increase with a total issue amount of CHF 20 million as well as on the financing of …
20.06.2023
Santhera Pharmaceuticals (SIX: SANN) has signed an exclusive license and collaboration agreement for vamorolone in North America (NA) with Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX).